TI
ADAP

Tidal Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Tidal Investments’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,554
Closed -$55K – 1003
2021
Q3 		$55K Buy
+10,554
New +$47.3K ﹤0.01% 878

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tidal Investments's ADAP Position: Q4 2021 in Review

Tidal Investments sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 10,554 shares — an estimated $55K sold.

Tidal Investments first reported a position in ADAP in Q3 2021 and held it in 1 quarter. The position peaked at $55K in Q3 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

  • Tidal Investments reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Tidal Investments sold 10,554 Adaptimmune Therapeutics shares in Q4 2021, an estimated $55K.
  • Tidal Investments first reported a position in Adaptimmune Therapeutics in Q3 2021 and held it in 1 quarter.
  • Tidal Investments's Adaptimmune Therapeutics position peaked at $55K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Tidal Investments's 13F filing for Q4 2021, filed 16 Feb 2022.